80234-20-4

Basic information

• Product Name: desdimethyltamoxifen
• Synonyms: desdimethyltamoxifen;(Z)-1-[4-(2-AMinoethoxy)phenyl]-1,2-diphenylbut-1-ene;2-[4-[(1Z)-1,2-Diphenyl-1-butenyl]phenoxy]ethanaMine;Di-N-deMethyltaMoxifen;ICI 142268;N,N-DideMethyltaMoxifen;N,N-DidesMe
• CAS NO: 80234-20-4
• Molecular Formula: C₂₄H₂₅NO
• Molecular Weight: 343.467
• Product Categories: Amines;Aromatics;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 80234-20-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 481.1°Cat760mmHg
• Flash Point: 235.5°C
• Appearance: /
• Density: 1.074g/cm³
• Vapor Pressure: 2.04E-09mmHg at 25°C
• Refractive Index: 1.6
• CAS DataBase Reference: desdimethyltamoxifen(CAS DataBase Reference)
• NIST Chemistry Reference: desdimethyltamoxifen(80234-20-4)
• EPA Substance Registry System: desdimethyltamoxifen(80234-20-4)

Safety Data

• Hazardous Substances Data: 80234-20-4(Hazardous Substances Data)

Usage

Uses

N,N-Didesmethyltamoxifen is a metabolite of Tamoxifen (T006000) that is formed in humans and nonhuman primates but not in rats.

InChI:InChI=1/C24H25NO/c1-2-23(19-9-5-3-6-10-19)24(20-11-7-4-8-12-20)21-13-15-22(16-14-21)26-18-17-25/h3-16H,2,17-18,25H2,1H3/b24-23-

Upstream product

• 10540-29-1 tamoxifen 

Downstream Products

• 80234-24-8 Guanidinotamoxifen 

Relevant articles and documents

TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

COMPOUNDS AND METHODS FOR 18F LABELED AGENTS

The present invention relates to novel compounds suitable for or already radiolabeled with 18F, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characterized by Formula II, wherein the substituents G, Q, L, Y and U have the meaning as defined in the specification and claims.